24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
ALIMLIEVA 100MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | ALIMLIEVA 100MG |
|---|---|
| Composition | Pemetrexed Injection IP 100mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
ALIMLIEVA 100MG (Pemetrexed Injection IP 100mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
ALIMLIEVA 100 MG (Pemetrexed Injection IP 100 mg) is a prescription anticancer medicine containing Pemetrexed 100 mg, an antifolate chemotherapy agent used in the treatment of specific cancers, particularly Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma. It belongs to a class of medicines known as Antifolate Antineoplastic Agents, which work by interfering with the production of DNA and RNA required for cancer cell growth and survival.
Cancer cells require folate-dependent enzymes to replicate and spread. Pemetrexed blocks multiple enzymes involved in the synthesis of nucleic acids, thereby preventing cancer cells from multiplying and promoting their destruction. This mechanism helps slow disease progression and improve treatment outcomes.
ALIMLIEVA 100 MG is commonly used as part of combination chemotherapy regimens, maintenance therapy programs, and individualized dosing schedules. The 100 mg strength allows oncologists to accurately adjust treatment doses according to a patient’s body surface area (BSA), treatment protocol, and clinical requirements.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in cancer treatment.
ALIMLIEVA 100 MG is commonly prescribed for:
Manufactured according to stringent pharmaceutical quality standards, ALIMLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pemetrexed therapy generally require supplementation with folic acid and vitamin B12, along with routine blood tests and medical monitoring to reduce treatment-related side effects and optimize outcomes.
Due to its established efficacy in thoracic oncology, ALIMLIEVA 100 MG remains an important medicine in modern cancer care.
ALIMLIEVA 100 MG (Pemetrexed Injection IP 100 mg) is primarily used in the treatment and management of specific cancers.
The medicine is widely used in advanced and metastatic non-squamous NSCLC.
Pemetrexed may be prescribed as maintenance treatment after initial chemotherapy.
The medicine is commonly used in combination with platinum-based chemotherapy for mesothelioma treatment.
Doctors may recommend Pemetrexed as part of comprehensive thoracic oncology treatment programs.
The medicine is frequently administered alongside other anticancer agents.
The 100 mg strength helps facilitate flexible and patient-specific dosing schedules.
Pemetrexed helps control disease progression and improve treatment outcomes.
Pemetrexed belongs to a class of medicines known as Antifolate Anticancer Agents.
ALIMLIEVA works by:
This mechanism helps reduce cancer progression and supports effective treatment outcomes.
Like all medicines, ALIMLIEVA 100 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Weakness and tiredness are frequently reported.
Digestive discomfort may occur during treatment.
Reduced appetite may affect nutritional intake.
The medicine may reduce white blood cells, red blood cells, and platelet counts.
Inflammation or ulcers inside the mouth may develop.
Some patients may experience mild to moderate skin reactions.
Digestive disturbances may occur.
Some individuals may experience constipation.
Reduced white blood cell counts may increase susceptibility to infections.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of ALIMLIEVA 100 MG (Pemetrexed Injection IP 100 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the disease being treated.
Dosage is generally calculated according to body surface area.
Renal function is an important factor in dosage planning.
Regular laboratory monitoring helps guide treatment decisions.
Concurrent chemotherapy medicines may influence dosing schedules.
Before starting treatment, inform your doctor if you have:
Patients receiving Pemetrexed are generally advised to take:
These supportive therapies help reduce the risk of certain side effects.
Patients should also disclose all prescription medicines, supplements, vitamins, and herbal products they are taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is primarily used for the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.
Pemetrexed is an antifolate chemotherapy medicine that blocks enzymes required for cancer cell growth and replication.
Yes. Pemetrexed is a chemotherapy medicine belonging to the antifolate class.
These supplements help reduce the risk and severity of treatment-related side effects.
Yes. It is commonly prescribed as maintenance therapy for eligible NSCLC patients.
Yes. It may lower white blood cells, red blood cells, and platelet counts, requiring regular monitoring.
Yes. Kidney function is an important consideration during Pemetrexed therapy and should be monitored regularly.
Yes. This medicine should only be administered by qualified healthcare professionals experienced in oncology treatment.